WO2009003996A1 - Composition cosmetique amelioree d'eclaircissement de la peau - Google Patents
Composition cosmetique amelioree d'eclaircissement de la peau Download PDFInfo
- Publication number
- WO2009003996A1 WO2009003996A1 PCT/EP2008/058427 EP2008058427W WO2009003996A1 WO 2009003996 A1 WO2009003996 A1 WO 2009003996A1 EP 2008058427 W EP2008058427 W EP 2008058427W WO 2009003996 A1 WO2009003996 A1 WO 2009003996A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- skin lightening
- skin
- composition
- titanium dioxide
- particle size
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 64
- 206010040829 Skin discolouration Diseases 0.000 title claims abstract description 42
- 239000002537 cosmetic Substances 0.000 title claims abstract description 22
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims abstract description 78
- 239000004408 titanium dioxide Substances 0.000 claims abstract description 37
- 239000007854 depigmenting agent Substances 0.000 claims abstract description 19
- 239000011164 primary particle Substances 0.000 claims abstract description 8
- 239000002245 particle Substances 0.000 claims description 26
- 230000000475 sunscreen effect Effects 0.000 claims description 16
- 239000000516 sunscreening agent Substances 0.000 claims description 16
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 6
- 229930195729 fatty acid Natural products 0.000 claims description 6
- 239000000194 fatty acid Substances 0.000 claims description 6
- 239000011708 vitamin B3 Substances 0.000 claims description 5
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 claims description 4
- 229960001679 octinoxate Drugs 0.000 claims description 4
- 239000000344 soap Substances 0.000 claims description 3
- 239000011719 vitamin A Substances 0.000 claims description 3
- 239000011715 vitamin B12 Substances 0.000 claims description 3
- 239000011726 vitamin B6 Substances 0.000 claims description 3
- 239000011718 vitamin C Substances 0.000 claims description 3
- 239000011710 vitamin D Substances 0.000 claims description 3
- 239000011709 vitamin E Substances 0.000 claims description 3
- 239000011712 vitamin K Substances 0.000 claims description 3
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- FMRHJJZUHUTGKE-UHFFFAOYSA-N Ethylhexyl salicylate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1O FMRHJJZUHUTGKE-UHFFFAOYSA-N 0.000 claims 1
- 229940068171 ethyl hexyl salicylate Drugs 0.000 claims 1
- 125000000627 niacin group Chemical group 0.000 claims 1
- 210000003491 skin Anatomy 0.000 description 26
- 230000000694 effects Effects 0.000 description 12
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 11
- 239000006071 cream Substances 0.000 description 11
- 229960003966 nicotinamide Drugs 0.000 description 11
- 239000011570 nicotinamide Substances 0.000 description 11
- 235000005152 nicotinamide Nutrition 0.000 description 11
- 239000003981 vehicle Substances 0.000 description 8
- 239000000839 emulsion Substances 0.000 description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 208000012641 Pigmentation disease Diseases 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 210000000245 forearm Anatomy 0.000 description 4
- 230000037075 skin appearance Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 238000004945 emulsification Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- -1 nicotinyl amino Chemical class 0.000 description 3
- 230000037368 penetrate the skin Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 2
- 229960004705 kojic acid Drugs 0.000 description 2
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- VAMXMNNIEUEQDV-UHFFFAOYSA-N methyl anthranilate Chemical compound COC(=O)C1=CC=CC=C1N VAMXMNNIEUEQDV-UHFFFAOYSA-N 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- MEZZCSHVIGVWFI-UHFFFAOYSA-N 2,2'-Dihydroxy-4-methoxybenzophenone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1O MEZZCSHVIGVWFI-UHFFFAOYSA-N 0.000 description 1
- WHQOKFZWSDOTQP-UHFFFAOYSA-N 2,3-dihydroxypropyl 4-aminobenzoate Chemical compound NC1=CC=C(C(=O)OCC(O)CO)C=C1 WHQOKFZWSDOTQP-UHFFFAOYSA-N 0.000 description 1
- WSSJONWNBBTCMG-UHFFFAOYSA-N 2-hydroxybenzoic acid (3,3,5-trimethylcyclohexyl) ester Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C1=CC=CC=C1O WSSJONWNBBTCMG-UHFFFAOYSA-N 0.000 description 1
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
- MVQVNTPHUGQQHK-UHFFFAOYSA-N 3-pyridinemethanol Chemical class OCC1=CC=CN=C1 MVQVNTPHUGQQHK-UHFFFAOYSA-N 0.000 description 1
- VKQJNOVKUCAMEC-UHFFFAOYSA-N 6-ethyl-4-hexyl-2-phenyl-1h-benzimidazole-5-sulfonic acid Chemical compound N=1C=2C(CCCCCC)=C(S(O)(=O)=O)C(CC)=CC=2NC=1C1=CC=CC=C1 VKQJNOVKUCAMEC-UHFFFAOYSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- USSFUVKEHXDAPM-UHFFFAOYSA-N Nicotinamide N-oxide Chemical compound NC(=O)C1=CC=C[N+]([O-])=C1 USSFUVKEHXDAPM-UHFFFAOYSA-N 0.000 description 1
- SBLKVIQSIHEQOF-UPHRSURJSA-N Octadec-9-ene-1,18-dioic-acid Chemical compound OC(=O)CCCCCCC\C=C/CCCCCCCC(O)=O SBLKVIQSIHEQOF-UPHRSURJSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N aniline-p-carboxylic acid Natural products NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- YEAYGXLRPMKZBP-KQGICBIGSA-N bis(2-hydroxyethyl)azanium;(e)-3-(4-methoxyphenyl)prop-2-enoate Chemical compound OCCNCCO.COC1=CC=C(\C=C\C(O)=O)C=C1 YEAYGXLRPMKZBP-KQGICBIGSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229960004881 homosalate Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000001261 hydroxy acids Chemical class 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000036564 melanin content Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 230000003061 melanogenesis Effects 0.000 description 1
- 210000002780 melanosome Anatomy 0.000 description 1
- 229940102398 methyl anthranilate Drugs 0.000 description 1
- 229940013224 niacin / niacinamide Drugs 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229940116918 octadecenedioic acid Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- FJCFFCXMEXZEIM-UHFFFAOYSA-N oxiniacic acid Chemical compound OC(=O)C1=CC=C[N+]([O-])=C1 FJCFFCXMEXZEIM-UHFFFAOYSA-N 0.000 description 1
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 1
- 229960001173 oxybenzone Drugs 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 231100000075 skin burn Toxicity 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- CXVGEDCSTKKODG-UHFFFAOYSA-N sulisobenzone Chemical compound C1=C(S(O)(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC=CC=C1 CXVGEDCSTKKODG-UHFFFAOYSA-N 0.000 description 1
- 229960000368 sulisobenzone Drugs 0.000 description 1
- 230000008833 sun damage Effects 0.000 description 1
- 230000037072 sun protection Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/29—Titanium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
Definitions
- the present invention relates to cosmetic skin lightening composition and in particular to a skin lightening composition that delivers immediate improvements in skin appearance by providing enhanced instant brightness/glow along with the effects of lightening the skin.
- a tan is essentially the skins' way of increasing its defence against the onslaught of damaging ultra-violet. Tanning protects against sun damage principally by increasing the melanin content of the epidermis. Although more skin pigmentation improves sun protection, intentional UV induced tanning does not necessarily achieve an increase in protective pigmentation as an ultra-violet protective strategy.
- Melanin which is basically responsible for skin pigmentation is synthesised by melanocytes, a cell type present at dermis-epidermis junction, from an amino acid tyrosine. Tyrosine is acted upon by an enzyme tyrosinase which is the key enzyme in melanogenesis.
- the conventional skin lightening compositions are based on sunscreens which maintain skin colour against the ultra-violet light. They have been based on materials which absorb/block incident ultra-violet light of the wavelength which produces the tanning of the skin. Other approaches have been to use niacin/niacinamide or other skin lightening agents which are believed to control dispersion of melanosomes or inhibit tyrosinase. Sunscreens alone cannot lighten the skin significantly and their action on the skin is only to reduce the ingress of incident ultra-violet into the skin and is therefore effective only during the day.
- GB 1 533 1 19 discloses a combination of niacinamide and a suitable mixture of UV absorbers which absorb in the UV range of 290 nm to 360 nm.
- IN 169917 discloses the use of a silicone compound to synergistically enhance skin lightening benefits obtained from the combination of niacinamide and sunscreens.
- Certain inorganic substances have also been proposed for use as sunscreens which physically block exposure of the skin to ultra-violet rays.
- titanium dioxide having a very small particle size. This grade of titanium dioxide, designated as ultrafine TiO 2 , affords a good degree of sun blocking potential without causing any biological skin lightening effect.
- IN 172889 discloses the use of titanium dioxide at levels from 3% along with octyl methoxy cinnamate to provide protection from excessive exposure to ultra-violet rays over a broad range of wavelengths in the UV-A and UV-B regions.
- US 5 997 887 and US 5 997 890 disclose topical compositions comprising pigmentary grade particulate material such as titanium dioxide, with a particle size greater than 100nm to about 300nm along with an active vitamin B 3 useful for imparting an essentially immediate visual improvement in skin appearance.
- pigmentary grade particulate material such as titanium dioxide
- an object of the present invention is to provide a cosmetic skin lightening composition that delivers immediate improvements in skin appearance by providing enhanced instant glow along with enhanced effects of lightening the skin.
- compositions including titanium dioxide with a primary particle size in the range greater than 300 nm and up to 1000 nm that synergistically enhances skin lightening efficacy of skin lightening agents while delivering immediate improvements in skin appearance by providing an enhanced instant glow.
- the effects obtained on skin lightening is particularly surprising as titanium dioxide with a primary particle size range of greater than 300 nm and up to 1000 nm is not a sunscreen, does not penetrate the skin and is not a known skin lightening agent.
- the present invention relates to a cosmetic skin lightening composition including 0.1% to 10% by weight of one or more of skin lightening agent or a precursor thereof and 0.1 to 5% titanium dioxide with a primary particle size greater than 300 up to 1000 nm in a cosmetically acceptable vehicle.
- the particle size mentioned for the purposes of the present invention is as measured by the Mac-View particle size distribution (electron microscopy) method (Mountech Co. Ltd.)
- the present invention relates to a cosmetic skin lightening composition
- a cosmetic skin lightening composition comprising 0.1 % to 10% by weight of skin lightening agents selected from vitamins B 3 , B 6 , B 12 , C, E, A, D, K, or mixtures thereof, and 0.1 to 5% titanium dioxide with a primary particle size greater than 300 up to 1000 nm in a cosmetically acceptable vehicle.
- skin lightening agents selected from vitamins B 3 , B 6 , B 12 , C, E, A, D, K, or mixtures thereof, and 0.1 to 5% titanium dioxide with a primary particle size greater than 300 up to 1000 nm in a cosmetically acceptable vehicle.
- vitamins B 3 , B 6 , B 12 , C, E, A, D, K, or mixtures thereof selected from vitamins B 3 , B 6 , B 12 , C, E, A, D, K, or mixtures thereof
- titanium dioxide with 0.1 to 5% titanium dioxide with a primary particle size greater than 300 up to 1000 nm
- a cosmetic skin lightening composition as set forth hereinabove comprising 0.1 to 10 % by weight of at least one organic sunscreen.
- the invention composition additionally comprises 0.05% to 5% by weight ultra fine titanium dioxide with a particle size in the range 1 -100 nm.
- composition of the invention is reversible and without any side effects.
- composition according to the invention is active both during - A -
- sunscreens which can act only during the day and on both the photoexposed and non-photoexposed part of the skin.
- the skin lightening agent according to the invention is vitamin B 3 or a derivative thereof and is selected from the group consisting of niacinamide, nicotinic acid esters, non-vasodilating esters of nicotinic acid, nicotinyl amino acids, nicotinyl alcohol esters of carboxylic acids, nicotinic acid N-oxide, niacinamide N-oxide and mixtures thereof.
- compositions can be advantageously included in the composition to provide for synergistic skin lightening effects.
- Still other skin lightening agents useful to be incorporated in the composition are polyamino acid sequences with pi in the range 2 to 5.5, and the amino acid forming the polyamino acid sequence can be naturally occurring or synthetic, dextro or levo form, straight chain or cyclised with a molecular weight of 200-20000, hydroquinone and derivatives (eg.
- the skin lightening agent is employed at a concentration in the range from 0.1 % to 10%, preferably from 0.1 to 5%, more preferably from 0.2 to 1.5%, optimally from 0.3 to 1% by weight of the composition.
- the organic sunscreens used in the composition according to the invention may be selected from 4-tertiary butyl-4'-methoxy dibenzoylmethane, octyl methoxy cinnamate, benzophenone-3, benzophenone-4, benzophenone-8, diethanolamine methoxy cinnamate, ethyl dihydroxypropyl para amino benzoic acid, glyceryl PABA, homosalate, methyl anthranilate, salicylate, ethylhexyl 2-phenyl-benzimidazole-5-sulphonic acid and others known in the art or any other suitable mixtures thereof.
- the preferred organic sunscreens used in the composition according to the invention may be selected from 4-tertiary butyl-4'-methoxy dibenzoylmethane, octyl methoxy cinnamate or suitable mixtures thereof.
- the organic sunscreens at a concentration in the range from 0.1 to 10 %, preferably from 0.5 to 8%, more preferably from 1 to 5% by weight of the composition.
- Titanium dioxide
- the titanium dioxide may be selected from surface untreated, surface treated, hydrophilically or hydrophobically, powder form or predispersed or a mixture thereof.
- the preferred primary particle size of titanium dioxide used according to the invention is greater than 300 up to 1000 nm. It is preferred that the primary particle size is in the range 310-750 nm.
- the particle size mentioned for the purposes of the present invention is as measured by the Mac-View particle size distribution (electron microscopy) method.
- the composition additionally comprises 0.1 to 5% (preferably 0.2 to 0.8%) by weight of the composition of ultra fine or micronised titanium dioxide with a particle size in the range 1-100nm, preferably 1-50nm and more preferably 5-25nm.
- the micronised titanium dioxide is especially preferred. This has been found to give additional skin lightening benefits.
- the vehicle which forms part of the cosmetic composition is one or more substances which are cosmetically acceptable in that they will not harm the skin.
- Cosmetic compositions to deliver different benefit agents are prepared using different emulsifying systems and vehicles.
- the vehicles that can be used in the compositions according to the invention can include powder absorbents, binders and carriers, and liquids such as emollients, emulsifiers, propellants, solvents, humectants (e.g polyols, glycerol), thickeners (e.g. Carbopol 934), cetyl alcohol, esters, ethoxylated castor oil, paraffin oils, lanolin and its derivatives, fragrances, colourants and mixtures thereof.
- the compositions according to the invention for topical application to the skin can be in the form of conventional products such as lotions, powders, creams, ointments, sticks, aerosol and cleansing products.
- the vehicle is a vanishing cream base which comprises 5-25%, preferably 8-22%, more preferably 10-20%, and optimally 12-20% by weight Ci 2 -C 20 fatty acids and 0.1-10%, preferably 1-5% and optimally 1.5-4% by weight Ci 2 -C 20 fatty acid soap.
- Vanishing cream base is one of the preferred forms of such a cosmetically acceptable vehicle and gives a desirable matt feel to the skin.
- the cosmetic skin lightening composition in the form of a cream is prepared using the conventional process used for making oil-in-water emulsions.
- the titanium dioxide with a particle size greater than 300 up to 1000 nm according to the invention is preferably added during the emulsion process and more preferably is added mid way through the emulsion process.
- a human volunteer study was conducted by testing various compositions on 50 volunteers of Type IV to V skin (Fitzpatrick scale) who were screened and selected to have a similar kind of skin pigmentation.
- the compositions had niacinamide purchased from Veer Chemie Ltd., India as the skin lightening agent
- the inorganic sunscreen used was titanium dioxide with an average particle size of 15 nm sold by Tayca Corporation under the trade name MT100Z.
- the titanium dioxide with an average particle size of 400 nm sold by Tayca Corporation under the trade name MP40 was used in the experiments to test the efficacy of the formulations in accordance with the invention.
- compositions according to the invention and the respective controls were prepared in a vanishing cream base and the composition details are presented in table 1.
- the process used to manufacture the cream was a standard process used for oil-in-water emulsions where the water phase containing the polyol and preservatives was heated and alkali was added to it.
- the molten oil phase containing the fatty acid, fatty alcohol, etc. was then charged into the water phase in 2 parts - the first led to the formation of the soap and the second part formed the actual emulsion.
- the batch was repeatedly passed through a homogenizer until a smooth emulsion was formed. Titanium dioxide with an average particle size of 15 nm and the titanium dioxide with an average particle size of 400 nm were added during the emulsion process. Once the emulsion was formed, it was slowly cooled and niacinamide was added at around 40-50 0 C followed by other heat-labile ingredients including other actives. All the ingredients were gently mixed under vacuum and the batch was de-aerated prior to perfume addition.
- the sample cream was applied at a concentration of 2 mg/cm 2 to areas marked on the volar forearm of the individual volunteers and corresponding untreated areas were maintained for comparison.
- the volar forearm is chosen to minimise the effect of the sun and study the effect of the biological skin lightening.
- Cream was applied twice per day.
- the marked out areas were assessed over a period of 4 weeks without the presence of the cream to assess the biological skin lightening and the data presented is at the end of the period.
- the assessment was done by an expert panel on a colour scale considering the difference between the treated and untreated area of the forearms, and is presented as the extent of skin lightening in the table 1 that follows.
- the skin lightening scores presented in table 1 show that increasing the concentration of 15 nm titanium dioxide alone does not significantly improve the skin lightening scores and even a combination of enhanced levels of niacinamide, the skin lightening agent, and the 15nm titanium dioxide gives a marginal improvement in skin lightening benefit.
- sample cream according to example 1 that did not contain any titanium dioxide with a particle size of 400 nm and example 3 that contained 0.3% titanium dioxide with a particle size of 400 nm as described in table 1 was applied at a concentration of 2 mg/cm 2 to areas marked on the volar forearm of the individual volunteers. Volunteers and the expert panel members were asked to score the brightness of the skin and glow on the skin immediately after application of the cream and also after the composition had completely dried on the skin. Percentage members who stated that composition of example 3, "makes my skin bright" was 93% and "makes my skin glow” was 91%.
- compositions using 1.25% niacinamide along with MP40 titanium dioxide with a particle size in the range 400 nm and another set with 3.5% niacinamide and 100 - 300 nm particle size titanium dioxide were assessed in a human volunteer study as described above and the data are presented in table 4.
- aAvailable from the Proctor and Gamble Company Contains 3.5% w/w niacinamide and 1.4% w/w TiO 2 of particle size 100-300nm.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Cosmetics (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200880023468A CN101686913A (zh) | 2007-07-05 | 2008-07-01 | 改进的用于皮肤变淡的美容组合物 |
EP08761408A EP2167022A1 (fr) | 2007-07-05 | 2008-07-01 | Composition cosmetique amelioree d'eclaircissement de la peau |
MX2010000271A MX2010000271A (es) | 2007-07-05 | 2008-07-01 | Composicion cosmetica mejorada para aclarar la piel. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1286/MUM/2007 | 2007-07-05 | ||
IN1286MU2007 | 2007-07-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009003996A1 true WO2009003996A1 (fr) | 2009-01-08 |
Family
ID=39877936
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2008/058427 WO2009003996A1 (fr) | 2007-07-05 | 2008-07-01 | Composition cosmetique amelioree d'eclaircissement de la peau |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP2167022A1 (fr) |
CN (1) | CN101686913A (fr) |
MX (1) | MX2010000271A (fr) |
WO (1) | WO2009003996A1 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011089571A2 (fr) | 2010-01-21 | 2011-07-28 | L'oreal | Composition cosmétique comprenant au moins un composé fluorophore |
US20200085702A1 (en) * | 2016-12-22 | 2020-03-19 | L'oreal | Oil-in-water emulsion comprising a specific surfactant system |
JP2021519342A (ja) * | 2018-03-21 | 2021-08-10 | ベネター ジャーマニー ゲ−エムベーハー | 二酸化チタン |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5997887A (en) * | 1997-11-10 | 1999-12-07 | The Procter & Gamble Company | Skin care compositions and method of improving skin appearance |
WO2001070190A2 (fr) * | 2000-03-23 | 2001-09-27 | Unilever Plc | Compositions cosmetiques |
US20050013784A1 (en) * | 2001-02-08 | 2005-01-20 | The Procter & Gamble Company | Mask composition |
US20050019356A1 (en) * | 2003-07-25 | 2005-01-27 | The Procter & Gamble Company | Regulation of mammalian keratinous tissue using N-acyl amino acid compositions |
JP2006257021A (ja) * | 2005-03-17 | 2006-09-28 | Shiseido Co Ltd | 皮膚化粧料 |
-
2008
- 2008-07-01 WO PCT/EP2008/058427 patent/WO2009003996A1/fr active Application Filing
- 2008-07-01 EP EP08761408A patent/EP2167022A1/fr not_active Withdrawn
- 2008-07-01 MX MX2010000271A patent/MX2010000271A/es not_active Application Discontinuation
- 2008-07-01 CN CN200880023468A patent/CN101686913A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5997887A (en) * | 1997-11-10 | 1999-12-07 | The Procter & Gamble Company | Skin care compositions and method of improving skin appearance |
WO2001070190A2 (fr) * | 2000-03-23 | 2001-09-27 | Unilever Plc | Compositions cosmetiques |
US20050013784A1 (en) * | 2001-02-08 | 2005-01-20 | The Procter & Gamble Company | Mask composition |
US20050019356A1 (en) * | 2003-07-25 | 2005-01-27 | The Procter & Gamble Company | Regulation of mammalian keratinous tissue using N-acyl amino acid compositions |
JP2006257021A (ja) * | 2005-03-17 | 2006-09-28 | Shiseido Co Ltd | 皮膚化粧料 |
Non-Patent Citations (2)
Title |
---|
DATABASE WPI Week 200670, Derwent World Patents Index; AN 2006-673867, XP002502711 * |
POPOV ALEXEY P ET AL: "Effect of size of TiO2 nanoparticles embedded into stratum corneum on ultraviolet-A and ultraviolet-B sun-blocking properties of the skin", JOURNAL OF BIOMEDICAL OPTICS, SPIE, BELLINGHAM, WA, US, vol. 10, no. 6, 8 December 2005 (2005-12-08), pages 64037/1 - 64037/9, XP002435985, ISSN: 1083-3668 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011089571A2 (fr) | 2010-01-21 | 2011-07-28 | L'oreal | Composition cosmétique comprenant au moins un composé fluorophore |
US20200085702A1 (en) * | 2016-12-22 | 2020-03-19 | L'oreal | Oil-in-water emulsion comprising a specific surfactant system |
US11607374B2 (en) * | 2016-12-22 | 2023-03-21 | L'oreal | Oil-in-water emulsion comprising a specific surfactant system |
JP2021519342A (ja) * | 2018-03-21 | 2021-08-10 | ベネター ジャーマニー ゲ−エムベーハー | 二酸化チタン |
Also Published As
Publication number | Publication date |
---|---|
CN101686913A (zh) | 2010-03-31 |
EP2167022A1 (fr) | 2010-03-31 |
MX2010000271A (es) | 2010-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10241121B2 (en) | Method of selecting antioxidants for use in topically applied compositions | |
TWI337085B (en) | A synergistic skin lightening composition | |
AU652047B2 (en) | Reduction of ultra-violet photodamage with triesters of citric acid | |
US10463604B2 (en) | Skincare and/or make-up method providing protection against UV rays | |
JP2008540350A (ja) | 共役リノール酸およびナイアシンアミドを含む美白組成物 | |
CN101917961A (zh) | 限制由紫外辐射引起的皮肤色素沉积的化妆品组合物 | |
WO1998052525A1 (fr) | Produit antisolaire | |
US20030031634A1 (en) | Non-endocrine disrupting cytoprotective UV radiation resistant composition | |
CN104114143A (zh) | 用于防护皮肤对抗uv射线的化妆品套装 | |
CN107405273B (zh) | 个人护理组合物 | |
WO2009003996A1 (fr) | Composition cosmetique amelioree d'eclaircissement de la peau | |
WO2001070190A2 (fr) | Compositions cosmetiques | |
WO2015018606A1 (fr) | Composition cosmétique | |
US20070224136A1 (en) | Topical composition and method for improving skin characteristics | |
EA023987B1 (ru) | Фотозащитная композиция для личной гигиены | |
AU730661B2 (en) | Sunscreen composition | |
US9694215B2 (en) | Skin compositions and methods | |
Brown et al. | Sun damage and sunscreen preparations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880023468.5 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08761408 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2008761408 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12010500030 Country of ref document: PH |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2010/000271 Country of ref document: MX |